Drugs / 68Ga-HA-DOTATATE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03145857 | Mar 2020 → Aug 2040 expected | neuroendocrine neoplasm | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04888481 | Feb 2022 → Aug 2027 expected | neuroendocrine neoplasm | University of Alberta | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-HA-DOTATATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04888481 ↗ |
| Modality | Diagnostic / imaging agent | “a nuclear medicine test used to create pictures of the whole body” NCT03145857 ↗ |
| Route | Intravenous | “68Ga-HA-DOTATATE intravenous single-dose administration” NCT04888481 ↗ |